

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/785,320		ATTY. DOCKET NO.: P0453.70113US03	
		FILING DATE: February 24, 2004		CONFIRMATION NO.: 9706	
		APPLICANT: Foss et al.			
		GROUP ART UNIT: 1614		EXAMINER: Not Yet Assigned	
Sheet	1	of	1		

U.S. PATENT DOCUMENTS


Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
Mb	A55	5,804,595		Portoghese, <i>et al.</i>	09-08-1998
	A56	5,866,154		Bahal, <i>et al.</i>	02-02-1999
	A57	2003-0022909	A1	Moss, <i>et al.</i>	01-30-2003
	A58	2003-0124086	A1	Bentley, <i>et al.</i>	07-03-2003
	A59	2003-0191147	A1	Sherman, <i>et al.</i>	10-09-2003

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
Mb	B28	CA	2,064,373		Lilly (Eli) and Company	09-30-1992	
	B29	EP	506,468	A1	Eli Lilly and Company	09-30-1992	
	B30	EP	643,967	A2	Euro Celtique S.A.	03-22-1995	
	B31	WO	01/32180	A2	Rodeva Limited	05-10-2001	
	B32	WO	02/098422	A1	University of Chicago	12-12-2002	
	B33	WO	03/032990	A2	Shearwater Corporation	04-24-2003	
	B34	WO	2004/014291	A2	Moss	02-19-2004	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
Mb	C148	FARTHING et al., New drugs in the management of the irritable bowel syndrome. Drugs. 1998 Jul;56(1):11-21. Review.	
	C149	FINGL et al., Chapter 43: Laxatives and cathartics. In Pharmacological Basis of Therapeutics. 1980: 1002-5.	
	C150	SCHUBERT-ZSILAVECZ et al., Das reizdarmsyndrom irritable bowel syndrome. Deutsche apotheke zeitung. 2002 Aug 22; 142(34): 40-9.	Yes
	C151	TALLEY et al., Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol. 2003 Apr;98(4):750-8. Review.	
	C152	THOMPSON et al., Laxatives: clinical pharmacology and rational use. Drugs. 1980 Jan;19(1):49-58. Review.	


EXAMINER: 	DATE CONSIDERED: 12-12-05
---	---------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/785,320	ATTY. DOCKET NO.: P0453.70113US03
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: February 24, 2004	CONFIRMATION NO.: 9706
		APPLICANT: Foss et al.	
Sheet 1 of 2	GROUP ART UNIT: 1614		EXAMINER: Not Yet Assigned



U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		


FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
M6	C99	BICKEL, Stimulation of colonic motility in dogs and rats by an enkephalin analogue pentapeptide. Life Sci. 1983;33 Suppl 1:469-72.	
	C100	BRIX-CHRISTENSEN et al., Endogenous morphine is produced in response to cardiopulmonary bypass in neonatal pigs. Acta Anaesthesiol Scand. 2000 Nov;44(10):1204-8.	
	C101	BROWN et al., The use of quaternary narcotic antagonists in opiate research. Neuropharmacology. 1985 Mar;24(3):181-91. Review.	
	C102	FOSS et al., Methylnaltrexone reduces morphine-induced postoperative emesis by 30%. Anesth Analg. 1994;78:S119.	
	C103	HOWD et al., Naloxone and intestinal motility. Experientia. 1978 Oct 15;34(10):1310-1.	
	C104	KAUFMAN et al., Role of opiate receptors in the regulation of colonic transit. Gastroenterology. 1988 Jun;94(6):1351-6.	
	C105	KINSMAN et al., Effect of naloxone on feedback regulation of small bowel transit by fat. Gastroenterology. 1984 Aug;87(2):335-7.	
	C106	KROMER et al., Endogenous opioids, the enteric nervous system and gut motility. Dig Dis. 1990;8(6):361-73. Review.	
	C107	KROMER et al., The current status of opioid research on gastrointestinal motility. Life Sci. 1989;44(9):579-89. Review.	
	C108	LIVINGSTON et al., Postoperative ileus. Dig Dis Sci. 1990 Jan;35(1):121-32. Review.	
	C109	POLAK et al., Enkephalin-like immunoreactivity in the human gastrointestinal tract. Lancet. 1977 May 7;1(8019):972-4.	
	C110	RIVIÈRE et al., Fedotozine reverses ileus induced by surgery or peritonitis: action at peripheral kappa-opioid receptors. Gastroenterology. 1993 Mar;104(3):724-31.	
	C111	ROGER et al., Colonic motor responses in the pony: relevance of colonic stimulation by opiate antagonists. Am J Vet Res. 1985 Jan;46(1):31-5.	
	C112	SCHANG et al., Beneficial effects of naloxone in a patient with intestinal pseudoobstruction. Am J Gastroenterol. 1985 Jun;80(6):407-11.	
	C113	SCHANG et al., How does morphine work on colonic motility? An electromyographic study in the human left and sigmoid colon. Life Sci. 1986 Feb 24;38(8):671-6.	

M Carl Hoffman 12.12.05



FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/785,320	ATTY. DOCKET NO.: P0453.70113US03
		FILING DATE: February 24, 2004	CONFIRMATION NO.: 9706
		APPLICANT: Foss et al.	
		GROUP ART UNIT: 1614	EXAMINER: Not Yet Assigned
Sheet	2	of	2

Mb	C114	SCHILLER et al., Studies of the mechanism of the antidiarrheal effect of codeine. J Clin Invest. 1982 Nov;70(5):999-1008.		
	C115	TAGUCHI et al., Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med. 2001 Sep 27;345(13):935-40.		
	C116	YUAN et al., Effects of methylnaltrexone on chronic opioid induced gut motility and transit time changes. Br J Anaesth. 1998;81(1):94.		
—	C117	YUAN et al., Effects of methylnaltrexone on chronic opioid-induced gut motility and transit time changes. University of Leicester – Abstracts from the Eighth International Symposium on Pain, Anaesthesia and Endocrinology. 1997 September 18-19th.		

EXAMINER <i>Michael A. Foss</i>	DATE CONSIDERED <i>12-12-05</i>
---------------------------------	---------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: Not yet known		ATTY. DOCKET NO.: P0453.70113US03	
				FILING DATE: February 24, 2004		CONFIRMATION NO.:	
				APPLICANT: Foss, et al.			
				GROUP ART UNIT: Not yet known		EXAMINER: Not yet known	
Sheet	1	of	4				

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
M6	*A1	2001/0018413	A1	Crain, <i>et al.</i>	08-30-2001
	*A2	2002/0028825	A1	Foss, <i>et al.</i>	03-07-2002c
	*A3	2001/0033865	A1	Oshlack, <i>et al.</i>	10-25-2001
	*A4	2001/0036476	A1	Oshlack, <i>et al.</i>	11-01-2001
	*A5	2001/0047005	A1	Farrar, <i>et al.</i>	11-29-2001
	*A6	4,176,186		Goldberg, <i>et al.</i>	11-27-1979
	*A7	4,719,215		Goldberg	01-12-1988
	*A8	4,861,781		Goldberg	08-29-1989
	*A9	4,987,136		Kreek, <i>et al.</i>	01-22-1991
	*A10	5,102,887		Goldberg	04-07-1992
	*A11	5,270,328		Cantrell, <i>et al.</i>	12-14-1993
	*A12	5,472,943		Crain, <i>et al.</i>	12-05-1995
	*A13	5,512,578		Crain, <i>et al.</i>	04-30-1996
	*A14	5,767,125		Crain, <i>et al.</i>	06-16-1998
	*A15	5,811,451		Minoia, <i>et al.</i>	09-22-1998
	*A16	5,866,164		Kuczynski, <i>et al.</i>	02-02-1999
	*A17	5,958,452		Oshlack, <i>et al.</i>	09-28-1999
	*A18	5,972,954		Foss, <i>et al.</i>	10-26-1999
	*A19	6,096,756		Crain, <i>et al.</i>	08-01-2000
	*A20	6,194,382	B1	Crain, <i>et al.</i>	02-27-2001
	*A21	6,261,599	B1	Oshlack, <i>et al.</i>	07-17-2001
	*A22	6,274,591	B1	Foss, <i>et al.</i>	08-14-2001
	*A23	6,395,705	B2	Crain, <i>et al.</i>	05-28-2002
	*A24	6,419,959	B1	Walter, <i>et al.</i>	07-16-2002
	*A25	6,451,806	B2	Farrar	09-17-2002
	*A26	6,559,158	B1	Foss, <i>et al.</i>	05-06-2003
	*A27	6,608,075	B1	Foss, <i>et al.</i>	08-19-2003
	*A28	RE36,547		Crain, <i>et al.</i>	02-01-2000
	*A29	2002/0188005	A1	Farrar, <i>et al.</i>	12-12-2002

Michael Steffo

12/2005

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: Not yet known	ATTY. DOCKET NO.: P0453.70113US03
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: February 24, 2004	CONFIRMATION NO.: Not yet known
		APPLICANT: Foss, et al.	
		GROUP ART UNIT: Not yet known	EXAMINER: Not yet known
Sheet	2	of	4

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
M6	*B1	AU	610,561		Shelley	08-17-1988	
	*B2	CA	1,315,689		The University of Chicago	04-06-1993	
	*B3	EP	0278821	A1	Shelly (Abstract)	08-17-1988	
	*B4	EP	0352361	A1	The Rockefeller University	01-31-1990	
	*B5	EP	278,821	A1	Marc Yves Shelly (Derwent Abstract)	08-17-1988	
	*B6	EP	306,575	B1	The Univ. of Chicago	03-15-1989	
	*B7	EP	352,361	A1	The Rockefeller University	01-31-1990	
	*B8	EP	760,661	B1	Minoia, et al.	12-30-1998	
	*B9	JP	2,625,457	B2	Goldberg (Derwent Abstract)	07-02-1997	
	*B10	NZ	222,911		The Univ. of Chicago	12-14-1987	
	*B11	WO	83/03197	A1	The Rockefeller University	09-29-1983	
	*B12	WO	88/05297	A1	Shelly	07-28-1988	
	*B13	WO	95/31985	A2	Minoia, et al.	11-30-1995	
	*B14	WO	97/33566		Alza Corp.	09-18-1997	
	*B15	WO	98/25613		Klinge Pharma GmbH	06-18-1998	yes
	*B16	WO	01/13909	A2	Critical Care Pharm.	03-01-2001	
	*B17	WO	01/37785	A2	Adolor Corp.	05-31-2001	
	*B18	WO	01/41705	A2	Adolor Corp.	06-14-2001	
	*B19	WO	01/42207	A2	Adolor Corp.	06-14-2001	
	*B20	WO	01/85257	A2	Pain Therapeutics, Inc..	11-15-2001	
	*B21	WO	02/060870	A2	Adolor Corp.	08-08-2002	


OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
M6	*C1	AKINBAMI, et al., <i>Neuroendocrinology</i> , (1994), 59(4), 343-348	
	*C2	AMIN, et al., <i>Anesth. Analg.</i> (1994), 78(4), 701-5	
	*C3	AMIR, <i>Brain Res.</i> (1984) 297:187-90.	
	*C4	AMIR, et al., <i>Arch. Toxicol. Suppl.</i> , (1983), 6, 261-5	
	*C5	ARGENTIERI, et al., <i>Brain Res.</i> (1983), 277(2), 377-9	
	*C6	BARATTI, et al., <i>Methods Find. Exp. Clin. Pharmacol.</i> , (1990), 12(7), 451-6	
	*C7	BEDINGFIELD, et al., <i>Alcohol</i> 15 (1): (1998), p51-54	
	*C8	BIANCHETTI, et al., <i>Life Sciences</i> (1983) 33(1), 415-18	
	*C9	BIANCHI, et al., <i>Life Sci.</i> , (1982), 30(22), 1875-83	
	*C10	BLANK, et al., <i>Life Sciences</i> . (1986), 39(17), 1493-9	
	*C11	BROWN, et al., <i>Brain Res.</i> , (1981), 221(2), 432-6	
	*C12	BROWN, et al., <i>Neuropharmacology</i> (1983), 3A (22), 317-21	
	*C13	CALCAGNETTI, <i>Pharmacol Biochem Behav</i> 1987 Jul;27(3):529-31 (Abstract only)	

Michael J. Foss 12.2.05

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: Not yet known		ATTY. DOCKET NO.: P0453.70113US03	
				FILING DATE: February 24, 2004		CONFIRMATION NO.: Not yet known	
				APPLICANT: Foss, et al.			
				GROUP ART UNIT: Not yet known		EXAMINER: Not yet known	
Sheet	3	of	4				

M6	*C14	CHANG, et al., <i>J. Pharmacol. Exp. Ther.</i> (1984), 228(2), 364-9		
	*C15	CULPEPPER, et al., <i>Clinical Trials and Therapeutics</i> (1992) 52, 90-95		
	*C16	EISENBERG, <i>Life Sciences</i> , (1984), 34(12), 1185-91		
	*C18	FERNANDEZ-TOME, et al., <i>Pharmacol. Biochem. & Behavior</i> (1988) 29, 387-392		
	*C19	FOSS, <i>Am. Journal of Surgery</i> (2001) 182, 195-265		
	*C20	FOSS, et al., <i>Anesthesiology</i> , (1995), 83(3A), p. A361		
	*C21	FOSS, et al., <i>Cancer Chemother. Pharmacol.</i> (1998), 42(4), 287-291		
	*C22	FOSS, et al., <i>J. Clin. Pharmacol.</i> , (1997), 37(1) 25-30		
	*C23	FOSS, et al., <i>J. Clin. Pharmacol.</i> (1993), 33(8), 747-51		
	*C24	FOSS, et al., <i>Life Sciences</i> 59(15), (1996), p. PL235-PL238		
	*C25	FRANCE, et al., <i>Neuropharmacology</i> (1987), 26(6), 541-8		
	*C26	FRANCE, et al., <i>Pharmacol. Biochem. & Behavior</i> (1985) 23, 731-736		
	*C27	FRIEDMAN, et al., <i>Ann. Pharmacother.</i> , (2001), 35(1) 85-91		
	*C28	GMEREK, et al., <i>J. Pharmacol. Exp. Ther.</i> (1986), 236(1), 8-13		
	*C29	HEIN, et al., <i>J. Pharmacol. and Exper. Therapeutics</i> (1981), 218(1), 7-15		
	*C30	JALOWIEC, et al., <i>Pharmacol. Biochem. & Behav.</i> , (1989), 33(3), 697-700		
	*C31	JANCOVIC and RADULOVIC., <i>Immunopharmacology</i> (1994), 28, 105-112		
	*C32	KIM, et al., <i>Chromatographia</i> , (1989), 28(7-8), 359-63		
	*C33	KOBLISH, et al., <i>Society for Neuroscience Abstracts</i> , (2001)27 (2), 2407		
	*C34	KOBYLECKI, et al., <i>Journal of Medicinal Chemistry</i> (1982), 25 (11) 1278-80		
	*C35	KOCZKA, et al., <i>Acta Chimica Academica Scien. Hung.</i> (1967) 51(4), 393-02		
	*C36	KOOB, et al., <i>J. Pharmacol. Exp. Ther.</i> (1984), 229(2), 481-6		
	*C37	KOTAKE, et al., <i>Xenobiotica</i> , 1989, 19(11), 1247-54		
	*C38	LEANDER, et al., <i>J. Pharmacol. Exp. Ther.</i> (1983), 224(1), 89-94		
	*C39	LITTLE, et al., <i>Society for Neuroscience Abstracts</i> , 27 (2); 2001, p. 2407		
	*C40	LYDON, et al., <i>European Journal of Anesthesiology</i> , 18 (Supplement 21), p. 92, 2001 (Abstract)		
	*C41	LYSLE, et al., <i>Brain, Behavior and Immun.</i> (1992) 6, 179-188		
	*C42	MAGNAN et al., <i>Naunyn Schmiedeberg's Arch Pharmacol.</i> (1982) 319(3), 197-205		
	*C43	MANARA, et al., <i>Adv. Endog. Exog. Opioids, Poroc. Int. Narc. Res. Conf.</i> , 12th (1981), 402-4		
	*C44	MANARA, et al., <i>Ann. Rev. Pharmacol. Toxicol.</i> (1985) 25, 249-73		
	*C45	MICKLEY, et al., <i>Physiology & Behavior</i> , 1985, 35(2), p. 249-53		
	*C46	MISRA, et al., <i>J. Pharm. Pharmacol.</i> (1987), 39(3), 225-7		
	*C47	MOERMAN, et al., <i>Acta Anesthologica Belgica</i> (1995), 3-4 (46) p. 127-32		
	*C48	MOSS, et al., <i>N. Engl. J. Med.</i> , (2002) 346 (6), 455		
	*C49	MUCHA, <i>Brain Research</i> (1987) 418, 214-220		
	*C50	MUCHA, <i>Life Sci.</i> (1989), 45, p. 671-678		
	*C51	MURPHY, et al., <i>Anesthesiology</i> (1999) 91 (3A), A349, (Abstract)		
	*C52	MURPHY, et al., <i>Anesthesiology</i> , (1997), 87(4), 765-770		
	*C53	MURPHY, et al., <i>Br. J. Anaesth.</i> (2001), 86(1) 120-122		
	*C54	MURPHY, et al., <i>J. Cardiovasc. Pharmacol.</i> , 1999, 33(1) 122-125		
	*C55	NARANJO, et al., <i>Life Sciences</i> (1986) 38(21) p. 1923-30		
	*C56	NELSON, <i>Dissertation Abstracts International</i> , (62/03-B), p. 1635 (Abstract)		
	*C57	ODIO, et al., <i>Pharmacology Biochemistry & Behavior</i> , (1990), 35(4) 963-9		
	*C58	Oncology (1996) 10(12):1880. (No authors listed)		
	*C59	OSINSKI, et al., <i>J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.</i> (2002) 780(2), 251-259		
	*C60	PAPPAGALLO, <i>Am. Journal of Surgery</i> (2001) (Supp. to 11/01) 182, 11S-18S		



12.12.05

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: Not yet known		ATTY. DOCKET NO.: P0453.70113US03	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: February 24, 2004		CONFIRMATION NO.: Not yet known	
				APPLICANT: Foss, et al.			
				GROUP ART UNIT: Not yet known		EXAMINER: Not yet known	
Sheet	4	of	4				


MG	*C61	POWELL, et al., <i>J. Pharmacol. & Exp. Therapeutics</i> (2002) 300(2), 588-596		
	*C62	QUOCK, et al., <i>J. Bioelectr.</i> (1986), 5(1), 35-46		
	*C63	QUOCK, et al., <i>Life Sciences</i> , (1985), 37(9), 819-26		
	*C64	QUOCK, et al., <i>Prog. Neuro. Psychopharmacol. Biol. Psychiatry</i> (1985), 9(3), 239-43		
	*C65	RAMABADRAN, <i>Life Sciences</i> , 1982, 31(12-13), 1253-6		
	*C66	ROBINSON, et al., <i>The Lancet</i> (1991) 338, 581-582		
	*C67	RUSSELL, et al., <i>Eur. J. Pharmacol.</i> (1982), 78(3), 255-61		
	*C68	SCHAEFER, et al., <i>Pharmacol. Biochem. Behav.</i> (1985), 23(5), 797-802		
	*C69	SCHMIDHAMMER, et al., <i>Helv. Chim. Acta</i> (1994), Vol. 77, No. 6, p. 1585-9		
	*C70	SCHMIDHAMMER, et al., <i>Helv. Chim. Acta.</i> (1993) No. 1, p. 476-80		
	*C71	SCHOLZ, 2000, 63 (6) p. 103		
	*C72	SCHREIER, et al., <i>Proc. West. Pharmacol. Soc.</i> (1982), 25, 151-4		
	*C73	SOLVASON, et al., <i>Brain, Behav., Immun.</i> (1989), 3(3), 247-262		
	*C74	SWAN, et al., <i>AIDS Research</i> , NIDA Notes, (1995), 10(3), 1-6		
	*C75	SYKES, <i>The Lancet</i> (1991), 337, 1475		
	*C76	THOMPSON, et al., <i>Brain Res.</i> (1996) 743, 184-201		
	*C77	UKAI, et al., <i>Psychopharmacology</i> (1987), 91(3), 279-84		
	*C78	VALENTINO, et al., <i>J. Pharmacol. Exp. Ther.</i> , (1981), 217(3), 652-9		
	*C79	VALENTINO, et al., <i>Life Sciences.</i> , (1983), 32(25), 2887-96		
	*C80	WALKER, et al., <i>Psychopharmacology</i> (1991), 104(2), p. 164-6		
	*C81	WARREN et al., <i>J. Pharmacol. Exp. Ther.</i> (1985), 235(2), p. 412-17		
	*C82	WILLETTE, et al., <i>Res. Commun. Subst. Abuse</i> (1983), 4(4), 325-37		
	*C83	YUAN et al., <i>Drug Dev. Res.</i> (2000) 50(2), 133-141		
	*C84	YUAN et al., <i>Neuropharmacology</i> (March 1999), 38(3) 425-432		
	*C85	YUAN, et al., <i>Anesthesiology</i> , Sept. (1995), 83 (3A), p A358 (Abstract)		
	*C86	YUAN, et al., <i>Anesthesiology</i> , Sept. (1995), 83 (3A), p A360 (Abstract)		
	*C87	YUAN, et al., <i>Anesthesiology</i> , Sept. (1999), 91 (3A) p. A349 (Abstract)		
	*C88	YUAN, et al., <i>Anesthesiology</i> , Sept. (1999), 91 (3A) p. A973 (Abstract)		
	*C89	YUAN, et al., <i>Clin. Pharmacol. Ther.</i> (2000), 67(4) 398-404		
	*C90	YUAN, et al., <i>Clin. Pharmacol. Ther.</i> (1997), 61(4), 467-475		
	*C91	YUAN, et al., <i>Clin. Pharmacol., Ther.</i> , (1996), 59(4), 469-475		
	*C92	YUAN, et al., <i>Clinical Pharmacology & Therapeutics</i> (1995) 57(2), p. 138		
	*C93	YUAN, et al., <i>Drug Alcohol Depend.</i> (1998), 52(2), 161-165		
	*C94	YUAN, et al., <i>European Journal of Pharmacology</i> (1995), 276 p. 107-111		
	*C95	YUAN, et al., <i>J. Pharmacol. Exp. Ther.</i> (US)300 (1), 2002, pp. 118-123		
	*C96	YUAN, et al., <i>JAMA</i> 284, No. 11, (2000), p 1383-1384		
	*C97	YUAN, et al., <i>JAMA</i> , (2000), 283 (3), 367-372		
	*C98	YUAN, et al., <i>Pain</i> (1999) 83, 631-635		

EXAMINER	DATE CONSIDERED 12-12-05
----------	---

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/358,560, filed February 4, 2003, and prior application, Serial No. 10/278,630, filed October 23, 2002, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/785,320	ATTY. DOCKET NO.: P0453.70113US03
		FILING DATE: February 24, 2004	CONFIRMATION NO.: 1614
		APPLICANT: Foss et al.	
		GROUP ART UNIT: 1614	EXAMINER: Not Yet Assigned
Sheet	1	of	3

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
MG	A30	4,311,833		Namikoshi, <i>et al.</i>	01-19-1982
	A31	4,377,568		Chopra, <i>et al.</i>	03-22-1983
	A32	4,385,078		Onda, <i>et al.</i>	05-24-1983
	A33	4,457,907		Porter, <i>et al.</i>	07-03-1984
	A34	4,462,839		McGinley, <i>et al.</i>	07-31-1984
	A35	4,518,433		McGinley, <i>et al.</i>	05-21-1985
	A36	4,556,552		Porter, <i>et al.</i>	12-03-1985
	A37	4,606,909		Bechgaard, <i>et al.</i>	08-19-1986
	A38	4,615,885		Nakagame, <i>et al.</i>	10-07-1986
	A39	4,670,287		Tsuji, <i>et al.</i>	06-02-1987
	A40	4,857,833		Sherman, <i>et al.</i>	08-15-1999
	A41	4,888,346		Bihari, <i>et al.</i>	12-19-1989
	A42	5,426,112		Zagon, <i>et al.</i>	06-20-1995
	A43	5,536,507		Abramowitz, <i>et al.</i>	07-16-1996
	A44	5,567,423		Ying, <i>et al.</i>	10-22-1996
	A45	5,591,433		Michael, <i>et al.</i>	01-07-1997
	A46	5,597,564		Ying, <i>et al.</i>	01-28-1997
	A47	5,609,871		Michael, <i>et al.</i>	03-11-1997
	A48	5,614,222		Kaplan, <i>et al.</i>	03-25-1997
	A49	5,626,875		Ballester Rodes, <i>et al.</i>	05-06-1997
	A50	5,629,001		Michael, <i>et al.</i>	05-13-1997
	A51	6,025,154		Li, <i>et al.</i>	02-15-2000
	A52	6,353,004	B1	Farrar, <i>et al.</i>	03-05-2002
	A53	6,469,030	B2	Farrer, <i>et al.</i>	10-22-2002
	A54	2001/0036951	A1	Farrar, <i>et al.</i>	11-01-2001

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
MG	B22	AU	758,416		Arch Development Corp.	07-03-1999	
	B23	CA	2,312,234		Arch Development Corp.	05-14-1999	
	B24	DE	3,780,819		Univ. of Chicago	1-14-93	
	B25	EP	1,047,726	A1	Quest International B.V.	07-22-1999	
	B26	WO	99/22737	A1	Arch Development Corp.	05-14-1999	
	B27	WO	04/043964	A2	Mallinckrodt	05-27-2004	

Michael Gelfo

12-12-05

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/785,320		ATTY. DOCKET NO.: P0453.70113US03	
				FILING DATE: February 24, 2004		CONFIRMATION NO.: 1614	
				APPLICANT: Foss et al.			
				GROUP ART UNIT: 1614		EXAMINER: Not Yet Assigned	
Sheet	2	of	3				

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
M6	C118	ALTIER et al., Opioid receptors in the ventral tegmental area contribute to stress-induced analgesia in the formalin test for tonic pain. Brain Res. 1996 Apr 29;718(1-2):203-6.	
	C119	BAKER et al., Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice. J Pharmacol Exp Ther. 2002 Sep;302(3):1253-64.	
	C120	BASILISCO et al., Oral naloxone antagonizes loperamide-induced delay of orocecal transit. Dig Dis Sci. 1987 Aug;32(8):829-32.	
	C121	BASILISCO et al., Effect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath test. Gut. 1985 Jul;26(7):700-3.	
	C122	BOWEN et al., Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys. J Pharmacol Exp Ther. 2002 Jul;302(1):264-73.	
	C123	BOWEN et al., College on Problems of Drug Dependence 64th Annual Scientific Meeting. June 8-13, 2002. Quebec City, Quebec, Canada. Abstracts. Drug Alcohol Depend. 2002 May 1;66 Suppl 1:S1-220. Abstract No. 65.	
	C124	CARR et al., Naltrexone antagonizes the analgesic and immunosuppressive effects of morphine in mice. J Pharmacol Exp Ther. 1994 May;269(2):693-8.	
	C125	CHOI et al., Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage. 2002 Jul;24(1):71-90. Review.	
	C126	CHOI et al., Inhibition of chemokine-induced chemotaxis of monkey leukocytes by mu-opioid receptor agonists. In Vivo. 1999 Sep-Oct;13(5):389-96.	
	C127	DE PONTI et al., Methylnaltrexone Progenics. Curr Opin Investig Drugs. 2002 Apr;3(4):614-20. Review.	
	C128	FLORES et al., Mechanisms of morphine-induced immunosuppression: effect of acute morphine administration on lymphocyte trafficking. J Pharmacol Exp Ther. 1995 Mar;272(3):1246-51.	
	C129	GILES et al., Quaternary opiate antagonists lower blood pressure and inhibit leucine-enkephalin responses. Eur J Pharmacol. 1983 Nov 25;95(3-4):247-52.	
	C130	HO et al., Suppression of immunological functions in morphine addicted mice. NIDA Res Monogr. 1986;75:599-602.	
	C131	KEHLET et al., Review of postoperative ileus. Am J Surg. 2001 Nov;182(5A Suppl):3S-10S. Review.	
	C132	KOSTEN et al., Naltrexone and morphine alter the discrimination and plasma levels of ethanol. Behav Pharmacol. 1999 Feb;10(1):1-13.	
	C133	KOSTIC, CAS Abstract Document No. 127: 13345, 1997.	
	C134	LI et al., Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis. 2002 Jan 1;185(1):118-22. Epub 2001 Dec 14.	
	C135	MACK, Paralytic ileus: response to naloxone. Br J Surg. 1989 Oct;76(10):1101.	
	C136	NEMETH-LEFKOWITZ et al., Research communication in Substances of Abuse (1980) 1(2): 177-83.	
	C137	PHAM et al., Drugs of Abuse: Chemistry, Pharmacology, Immunology and AIDS; National Institute of Drug Research 96: Monograph Series. U.S. Department of Health and Human Services; 1990.	
	C138	QUANG-CONTAGREL et al., Long-term methadone treatment: effect on CD4+ lymphocyte counts and HIV-1 plasma RNA level in patients with HIV infection. Eur J Pain. 2001;5(4):415-20.	
	C139	SAKURADA et al., Differential antagonism of endomorphin-1 and endomorphin-2 supraspinal antinociception by naloxonazine and 3-methylnaltrexone. Peptides. 2002 May;23(5):895-901.	
	C140	SANDNER-KEISLING et al., Pharmacology of opioid inhibition to noxious uterine cervical distension. Anesthesiology. 2002 Oct;97(4):966-71.	
	C141	SHAVIT et al., Effects of a single administration of morphine or footshock stress on natural killer cell cytotoxicity. Brain Behav Immun. 1987 Dec;1(4):318-28.	
	C142	SOLDANI et al., Central and peripheral involvement of mu receptors in gastric secretory effects of opioids in the dog. Eur J Pharmacol. 1985 Nov 19;117(3):295-301.	
	C143	STEINBROOK et al., An opioid antagonist for postoperative ileus. N Engl J Med. 2001 Sep 27;345(13):988-9.	

Michael Steffen

12/12/05

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/785,320		ATTY. DOCKET NO.: P0453.70113US03	
				FILING DATE: February 24, 2004		CONFIRMATION NO.: 1614	
				APPLICANT: Foss et al.			
				GROUP ART UNIT: 1614		EXAMINER: Not Yet Assigned	
Sheet	3	of	3				

M6	C144	WEI et al., Abstracts of the 2002 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. Atlanta, Georgia, USA. March 24-27, 2002. Clin Pharmacol Ther. 2002 Feb;71(2):P1-136.		
I	C145	WILMORE et al., Can we minimize the effects of opioids on the bowel and still achieve adequate pain control? Am J Surg. 2001 Nov;182(5A Suppl):1S-2S.		
I	C146	WYBRAN et al., Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes. J Immunol. 1979 Sep;123(3):1068-70.		
I	C147	YUAN, Clinical Status of Methylnaltrexone, A New Agent to Prevent and Manage Opioid-Induced Side Effects. J Support Oncol. 2004 Mar/Apr; 2(2):111-22.		

EXAMINER <i>Michael Steffen</i>	DATE CONSIDERED <i>12.12.05</i>
---------------------------------	---------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an IDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]